- Choosing a selection results in a full page refresh.
As a community of longevity experts, doctors, and scholars, EnerTiva is fully committed to the invaluable role research plays in medicine and the limitless opportunities it presents for the future. In that spirit, EnerTiva is proud to play a leading role in discovering new, scientifically proven treatment options that prevent age-related diseases and reverse age-related damage.
Active, Recruiting Participants
Completed
Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL)
Rapamycin is an FDA-approved antifungal agent, most used to prevent organ transplant rejection. Rapamycin targets the mTOR signaling pathway, which is associated with many aging-related diseases.
MEARL is a double-blind, randomized, placebo-controlled trial. Notably, it is the first nationwide telemedicine trial and the first large-scale intervention trial on longevity. MEARL is proudly sponsored by EnerTiva and affiliated with the University of California.
Completed
Pilot Study into Low Dose Naltrexone (LDN) and NAD+ for Treatment of Patients with Post-COVID-19.
Proudly sponsored by AgelessRx, this double-blind placebo-controlled pilot study will assess the use of Low Dose Naltrexone (LDN) and NAD+ for the treatment of patients with post-COVID-19 (long-COVID-19).
EnerTiva will enroll over 60 people (must have had a positive test for SARS-CoV-2 1-4 months before enrollment) for a 12-week study. Patients will receive LDN and NAD+ treatment or a corresponding placebo tablet and patch (control group) for the 12-week duration.
Thanks for subscribing!
This email has been registered!